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Background: Neutrophil (PMN) leukocytes participate to the initial phases of atherosclerosis through the release of
Interleukin 8 (CxCL8; IL-8) that contribute to amplification of inflammation. Aim of the study is to investigate the
production of IL-8 by PMN leukocytes from dyslipidemic patients treated with simvastatin.
Methods: In 15 dyslipidemic subjects with moderately increased cardiovascular risk, assessed by Framingham Risk
Score, blood samples were obtain to investigate PMNs IL-8 production [at baseline and after N-formyl-Met-Leu-Phe
(fMLP) stimulation] before and after long-term (1-year) simvastatin treatment.
Results: The resting release of IL-8 was higher in dyslipidemic patients at baseline when compared with control
subjects (p < 0.05). One year of treatment was significantly associated with reduced IL-8 production (p < 0.01).
Moreover, the fMLP-induced IL-8 production in dyslipidemic untreated patients was higher than that of controls
(p < 0.05) and was reduced after simvastatin treatment (p < 0.01). IL-8 release after 1 year of treatment was reduced
to levels which were lower than those observed in control subjects both for resting and stimulated cytokine
production (p < 0.01).
Conclusions: Prolonged treatment with simvastatin is associated with a reduction of IL-8 production, suggesting
the possibility of statin to modulate the pro-inflammatory response in PMNs of patients with moderately increased
cardiovascular risk.
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Inflammation plays a key role in the beginning and pro-
gression of atherosclerosis [1]. The relation of coronary
artery disease with systemic inflammation is confirmed
by the closely association between serum markers of in-
flammation and risk of cardiovascular events [2,3].
Polymorphonuclear leukocytes (PMNs) are effector
cells in many inflammatory conditions [4]. These cells
produce a large amount of reactive oxygen species, in-
volved in lipid oxidation [5]. In addition, stimulated and
activated PMNs release cytokines that produce impair-
ment of endothelial function [6]. On stimulation, PMNs* Correspondence: andrea.maresca@uninsubria.it
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unless otherwise stated.release cytokines such as IL-8 that promote endothelial
cell activation and may further affect their recruitment
[7]. As regards the functional alterations which occur at
the cellular level in atherosclerosis, although a primed
state of PMNs - associated with increased oxidative
stress, pro-inflammatory cytokine release and increased
Angiotensin II type 1 receptor expression - has been de-
scribed in humans with high cardiovascular risk, hyper-
cholesterolemia, hypertension, diabetes and renal failure,
only few data are reported about the potential role of
pharmacological treatment on the functional properties
of PMNs [8-13]. Previous studies from our group
showed that short-term simvastatin treatment was able
to affect PMNs functional responses [11-13], however
the effect of prolonged statin treatment on IL-8 produc-
tion has not yet been investigated. Aim of our study wasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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dyslipidemic patients treated with simvastatin.
Methods
Subjects
In 15 dyslipidemic patients at moderately increased car-
diovascular risk, assessed by Framingham Risk Score
[14], who had signed a written informed consent before
enrolling in the study, PMNs were isolated from venous
blood (see below) before any pharmacological treatment
and during short-term (1 month) and long-term (1 year)
simvastatin treatment (20 mg assumed at 10 PM) to in-
vestigate IL-8 cellular production.
Subjects were enrolled consecutively at our Lipid
Clinic (Clinical Medicine, University of Insubria, Varese,
Italy).
Inclusion criteria were:
 increased cardiovascular risk showing a “moderate
risk” for vascular events according to the National
Cholesterol Education Program - Adult Treatment
Panel III (ATPIII) guidelines [14]; patients enrolled
at “moderate risk” showed in fact two or more risk
factors and a 10-year cardiovascular risk < 20% when
calculated according to the Framingham algorithm.
 no disease (except dyslipidemia and/or mild
hypertension) found after a clinical examination and
routine laboratory tests.
 clinical indication of lipid-lowering pharmacological
treatment with statins
 no pharmacological treatment.
Exclusion criteria were:
 documented ischemic heart disease or
“equivalent ischemic heart disease” [14]
 diabetes
 ongoing clinical infection or presence of infections
in the previous three months
 smoking habitus
 competitive sporting activities.
After 6 weeks of life-style modification including die-
tary treatment (qualitative counselling) and recommen-
dations for mild physical activity, patients were asked to
maintain the same level of physical activity and a similar
diet throughout the study; besides the evaluations sche-
duled for the study on neutrophils at 1 month and 1 year,
patients were followed for clinical evaluations and stan-
dard laboratory exams after starting statin therapy.
A group of 15 healthy subjects selected from a popula-
tion evaluated for a general clinical check-up was also
enrolled: all patients were evaluated with a clinical visit
including familiar and personal history.Blood samplings were obtained to perform routine
laboratory exams and to isolate circulating PMNs by
using heparinized tubes between 8.00 and 9.00 AM, after
a fasting night. All patients were previously asked not
to take coffees, teas, chocolates or cola-containing sub-
stances for the 24 hours preceding the evaluations.
The following laboratory exams were performed:
 Haemocromocytometric exam, plasma creatinine,
urea, aspartate aminotransferase, alanine
aminotransferase, gamma glutamyl transpeptidase,
alkaline phosphatase, creatine kinase, thyroid
stimulating hormone, urinary proteins, plasma
protein electrophoresis, fasting glucose: they
resulted in the two groups within the normal limits
and no clinically relevant change was observed
during treatment (data not shown).
 Total cholesterol, high density lipoprotein-cholesterol
(HDL-c), low density lipoprotein-cholesterol (LDL-c),
triglycerides, apolipoprotein A, apolipoprotein B,
high-sensitive C-reactive protein (CRP).
The study protocol was approved by “Azienda Ospeda-
liera Ospedale di Circolo e Fondazione Macchi” Ethics
Committee.PMN isolation
Whole blood was allowed to sediment on dextran at 37°C
for 30 min. Supernatant was recovered and PMNs were
isolated by standard density-gradient centrifugation as
previously described [13]. Contaminating erythrocytes
were eliminated by 10 minutes hypotonic lysis in distilled
water with added NH4Cl 8.2 g/l, KHCO3 1.0 g/l, and
EDTA 37.0 mg/l. Cells were then washed three times in
NaCl 0.15 M. Purity and viability of PMNs preparations
were always >95% and no platelets or erythrocytes could
be detected either by light microscopic examination or by
flow cytometric analysis.PMN production of CXCL8
To assess IL-8 production, PMNs were re-suspended at
the concentration of 1×107 cells/ml in RPMI medium and
incubated alone (resting IL-8 production) or in the pre-
sence of 0.1 μM of fMLP (stimulated IL-8 production) at
37°C for 5 hours. After incubation, cells were centrifuged
(600 g, 5 min, 20°C) and supernatant was harvested for
IL-8 assay. IL-8 levels in PMN supernatants were quanti-
fied using a sandwich-type enzyme-linked immunosorbent
assay (ELISA kit; Amersham Biosciences, UK). Detection
limit of the assay was 1 pg/ml.
Levels of IL-8 were determined in a duplicate way and
production of PMNs IL-8 was measured in all patients
and controls.
Table 1 Clinical and demographic characteristics of






Age (years) 57 ± 11 53 ± 13 ns
Female (n, %) 8 (53%) 4 (27%) ns
BMI (kg/m2) 26 ± 2 26 ± 2 ns





9.5 ± 2.1 3.3 ± 1.8 0.01
BMI: body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure.
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Data are presented as mean ± standard deviation (SD) and
median and 25th-75th percentile range (IQR), as needed.
The levels of IL-8 had not a normal distribution, so we
have applied non-parametric tests. Comparisons between
dependent measures were performed with the Wilcoxon
test. The Bonferroni correction was applied for post-hoc
comparisons. Comparisons between independent mea-
sures were performed with the MannWhitney U test. The
mean difference and its 95% confidence interval (95% CI)
was computed to quantify both changes in time and dif-
ferences between cases and controls. Correlation analysis
was performed by Pearson test. Calculations were per-
formed using a commercial software (GraphPad Prism
version 4.00 for Windows, GraphPad Software, San Diego,
CA, USA, www.graphpad.com) and a two-sided P < 0.05
was retained for statistical significance.
Results
Baseline characteristics of dyslipidemic patients and con-
trols are shown in Table 1. The two groups were similar
for age, sex, BMI and blood pressure values.
No patients were lost to the follow up.Figure 1 IL-8 production in resting (left panel) and fMLP-induced (rig
during statin treatment. Horizontal lines represent the median values, bo
and maximum values. For comparison, data obtained in healthy controls ar
(dotted lines). * = P < 0.05 and ** = P < 0.01 vs control subjects. # = P < 0.01IL-8 production from PMNs of dyslipidemic patients and
controls
The resting release of IL-8 was different between controls
and dyslipidemic subjects at baseline [mean difference
(95% C.I.): −280.4 pg/ml (IQR: −454.0 to −106.8), p <
0.05]. One year of treatment significantly reduced IL-8
production [mean difference (95% C.I.): 399.5 pg/ml (IQR:
187.7 to 611.3)]. IL-8 production after 1 year of treatment
was reduced to levels which were lower than those ob-
served in control subjects [mean difference (95% C.I.):
119.1 pg/ml (IQR: 66.8 to 171.4)] (Figure 1, left panel).
Moreover, the fMLP-induced IL-8 production in un-
treated dyslipidemic patients was higher than that of
controls [mean difference (95% C.I.): −263.4 pg/ml
(IQR: −469.0 to −57.91), p < 0.05]. The stimulated IL-8
production was reduced after simvastatin treatment [mean
difference (95% C.I.): 543.9 pg/ml (IQR: 356.8 to 731.0)].
The values measured at 1-year follow-up were lower than
those observed in control subjects [mean difference (95%
C.I.): 280.5 pg/ml (IQR: 170.8 to 390.1)] (Figure 1, right
panel).
Basal levels of IL-8 didn’t correlate to age (r = 0.463,
P = ns), CRP (r = 0.341, P = ns), non-HDL cholesterol
(r = 0.317, P = ns) and apoB/apoA ratio (r = 0.301, P = ns).
We didn’t found a significant correlation between IL-8
reduction (from baseline to 1 year) and changes of other
parameters (LDL-cholesterol, CRP).
Clinical and lipid profile changes during statin treatment
in dyslipidemic patients
Body mass index and blood pressure values did not
significantly change during follow-up. The lipid profile of
patients and controls at baseline and after 1 year is shown
in Table 2. As expected, in dyslipidemic patients, total
cholesterol, LDL-c and apolipoprotein B were significantly
reduced at 1-year evaluation compared to baselineht panel) PMNs from dyslipidemic subjects before (baseline) and
xes represent the 25th-75th percentiles, and vertical bars the minimum
e also shown: median values (solid lines) with 25th-75th percentiles
vs baseline.
Table 2 Lipid profile of dyslipidemic patients and controls at baseline and after 1 year
Dyslipidemic patients (n = 15) Controls (n = 15)
Baseline After 1 year Baseline After 1 year
Total cholesterol (mg/dl) 276 (256–330) 204 (171–232)* 245 (188–266)° 188 (165–200)
HDL-cholesterol (mg/dl) 50 (47–57) 52 (49–65) 56 (47–63) 53 (46–65)
LDL-cholesterol (mg/dl) 202 (191–246) 118 (103–149)* 163 (116–175)° 112 (87–122)
Triglycerides (mg/dl) 141 (115–190) 144 (87–154) 159 (74–198) 133 (84–160)
Apoliprotein B (mg/dl) 164 (157–219) 100 (86–119)* 140 (119–157)° 149 (128–185)
Apoliprotein A (mg/dl) 143 (135–162) 141 (136–175) 105 (91–146) 99 (77–116)
*vs baseline (p < 0.0001).
°vs dyslipidemic patients at baseline (p < 0.001).
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vs 276 mg/dL (IQR: 256–330), P < 0.0001; LDLc: 118 mg/
dL (IQR: 103–149) vs 202 mg/dL (IQR: 191–246),
P < 0.0001; apolipoprotein B: 100 mg/dL (IQR: 86–119) vs
164 mg/dL (IQR: 157–219), P = 0.0001]. HDL-c, triglycer-
ides and apolipoprotein A did not significantly change
during follow-up. We performed a subgroup analysis by
gender (Table 3) and we observed a major reduction of
LDL-cholesterol in women. Moreover, CRP values was
significantly reduced during treatment [2.99 mg/L (IQR:
1.33-4.86) and 1.5 mg/L (IQR: 1.0-2.6), P < 0.01)].
Discussion
It is clear that atherosclerosis is a chronic disease of arte-
rial wall in which immuno-inflammatory mechanisms are
involved [15]. It is well known the role of monocytes, as
representatives of the innate immune system, in athero-
sclerosis development [16]. Since a body of research car-
ried out over the last decade has disclosed the complex
behaviour of PMNs, unraveling a key role in the onset and
progression of atheroma, we decided to focus our atten-
tion on these cells [17].
The main finding of this study is the observation that a
prolonged treatment with statin, in patients with increased
cardiovascular risk, is consistently associated with reduc-
tion in IL-8 cellular production by primed neutrophils.
Pathogenic effects of PMNs in atherosclerosis are mediated
through production of pro-inflammatory cytokines [IL-8,Table 3 Modification in lipid profile of dyslipidemic patients
Male (n = 7)
Baseline After
Total cholesterol (mg/dl) 260 (236–316) 208
LDL-cholesterol (mg/dl) 186 (172–207) 120
HDL-cholesterol (mg/dl) 50 (47–57) 54
Tryglicerides (mg/dl) 115 (87–134) 114
Apolipoprotein A (mg/dl) 141 (136–152) 136
Apolipoprotein B (mg/dl) 151 (139–168) 90 (
*vs baseline (p = 0.001).
+vs baseline (p = 0.05).tumor necrosis factor alpha (TNFa)] and reactive oxygen
species [18]. Chemokines are a number of small, inducible,
proinflammatory proteins that direct migration of circula-
ting leukocytes to sites of inflammation. This superfamily
is divided into α and β-chemokine subfamilies. IL-8 is one
of the main proinflammatory cytokine produced by neu-
trophils and it is the prototypical member of α-chemokine
subfamily [19-24]. Generation of IL-8 can be expected
upon infection, ischemia, trauma and other disturbances of
tissue homeostasis since the levels of IL-1 and TNFa,
which are important IL-8 inducers, are elevated. IL-8 is
likely to be the main cause of local accumulation of neutro-
phils [20]. IL-8 might have atherogenic function through
multiple actions: it facilitates recruitment of neutrophils
and T-lymphocytes into sub-endothelial space, monocytes
activation and adhesion to endothelium [21,22], migration
of vascular smooth muscle cells [22]. Macrophage-deri-
vated human foam cells contain high amounts of IL-8
[23,24]. It has also been reported that apparently healthy
subjects in the highest serum IL-8 level quartile had an in-
creased risk of coronary events when compared with those
in the lowest quartile [25].
In our study we observed a lack of significant cor-
relation between basal levels of IL-8 and age, CRP, non
HDL cholesterol and apoB/apoA ratio. Furthermore
despite a similar reduction after simvastatin treatment
(from baseline to 1 year) of IL-8, LDL cholesterol and
CRP, we did not see any significant correlation. Fromafter simvastatin treatment by gender
Female (n = 8)
treatment Baseline After treatment
(172–263) 299 (278–347) 199 (176–229)*
(99–160)+ 207 (187–244) 118 (142–203)*
(48–70) 51 (47–60) 52 (49–63)
(83–167) 180 (142–203) 149 (95–153)
(127–166) 145 (134–163) 147 (136–177)
85–126)+ 180 (136–269) 101 (91–119)*
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the small sample size of the study.
Statins have pharmacological activities independently of
their lipid-lowering action, that can be in part attributed
to their ability to interfere with inflammatory mechanisms
[26]. Among the several ancillary actions of statins, these
drugs are able to down-regulate expression of adhesion
molecules, to inhibit expression of chemokine monocyte
chemo-attractant protein-1 in activated leukocytes, to
block expression of integrins and to reduce monocytes
adhesiveness to endothelium [27-30]. As regards IL-8 pro-
duction by human neutrophils, it has been demonstrated
that simvastatin treatment could reduce peripheral blood
monocyte mRNA expression of IL-8 and IL-6 and mono-
cyte chemo-attractant protein-1 after 6 week of treatment
[31] and we reported that cellular PMNs IL-8 release was
reduced upon 1-month statin therapy [12]. In this study,
one year of simvastatin treatment reduced IL-8 produc-
tion in comparison to pre-treatment values, thus exclu-
ding the occurrence of a potential tolerance phenomenon
after long-term treatment. Moreover, IL-8 production
after 1 year of treatment was reduced to levels which were
lower than those observed in control subjects. Our results
seem to suggest that simvastatin can contribute to modu-
late inflammation by IL-8 reduction.
In our study simvastatin treatment reduced LDL choles-
terol in men and in women, but the degree of this lower-
ing was more evident in females. This result may be in
part due to a higher LDL cholesterol baseline value than
in men and to the prevalent menopausal status in enrolled
women. Nevertheless the small sample size (8 women)
does not allow to draw definitive conclusions. From recent
meta-analyses statin therapy is associated with significant
decreases in cardiovascular events and in all-cause mor-
tality in women and men [32].
The study has some limitations: 1) we have not col-
lected informations about subclinical atherosclerosis
(intima-media thickness, carotid plaque); 2) we have
evaluated IL-8 production as marker of inflammatory
response, but inflammation can also be evaluated by
several different parameters, such as IL-6, IL-15, TNFα,
not assessed in this study.Conclusions
Our results show an enhanced production of IL-8 in pa-
tients at moderately increased risk for vascular disease.
Simvastatin treatment is associated with a reduced pro-
duction of IL-8 from PMNs in a long-time treatment.Abbreviations
PMNs: Neutrophils, polymorphonuclear leukocytes; IL-8: CXCL8, interleukin-8;
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